AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients

  AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees,
                                   Patients

PR Newswire

NEW YORK, Jan. 2, 2013

NEW YORK, Jan. 2, 2013 /PRNewswire/ --AbbVie (NYSE:ABBV) today marks its
launch as an independent biopharmaceutical company, with employees from more
than 40 countries and patients joining AbbVie leaders as they ring the first
opening bell of 2013 at the New York Stock Exchange.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company

With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines
the focus and passion of a leading-edge biotech with the expertise and
structure of a long-established pharmaceutical leader. A global enterprise
that serves patients in more than 170 countries, AbbVie launches with an
estimated $18 billion in annual revenues and a strong commitment to creating
shareholder value through long-term growth potential and the continuation of
the company's history of shareholder dividends.

"Today AbbVie launches with an outstanding portfolio, a solid pipeline and
enthusiastic people who will serve patients and deliver growth," said Richard
A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "With
those assets and a relentless focus on innovation we intend to create
significant value for our shareholders."

Strong, Well-Managed Business and Product Portfolio
AbbVie launches with a team of experienced senior leaders who understand how
to manage AbbVie for long-term, profitable growth and who have the proven
ability to commercialize scientific discoveries for patients. As a
biopharmaceutical company, AbbVie has adopted a streamlined and focused
business model built on a broad portfolio of market leading medicines that
will enable AbbVie to invest in tomorrow's therapies.

The portfolio includes both growth brands and durable performers, including
HUMIRA, AndroGel, Lupron, Synagis[1], Creon, Synthroid, Kaletra, Norvir and
Zemplar.

Related information: www.abbvieinvestor.com

AbbVie's long-term growth will be fueled by a compelling pipeline of more than
20 mid- to late-stage clinical programs – as well as new discoveries to
address diseases including Hepatitis C, rheumatoid arthritis, psoriasis,
multiple sclerosis, Alzheimer's disease, Parkinson's disease,
spondyloarthropathies, multiple myeloma and endometriosis. AbbVie has tripled
the number of new molecular entities in its pipeline over the last several
years.

With these and other compounds in its pipeline, AbbVie is rapidly developing
therapies that have strong clinical performance, patient benefit and health
economic value.

Related information: www.abbvie.com/research-innovation/pipeline.html

AbbVie's Approach to Innovation
Making new discoveries and developing them into effective medicines is the
foundation of the company's mission and business. To accomplish those goals,
AbbVie's research is guided by a patient-driven research and development (R&D)
approach that begins with a deep understanding of the serious diseases that
are the company's focus, as well as careful evaluation of the current needs of
patients, payers and regulators worldwide. The company's scientists and
physicians focus their work on targets that have the best potential to
fundamentally transform the way diseases are treated in the future.

AbbVie is committed to an agile and collaborative approach to innovation,
across its global R&D and manufacturing sites. The company's scientists rely
on proprietary technologies and methods to help them more quickly advance the
most promising compounds from laboratory to clinical trials. AbbVie's research
operates with a collaborative model that seeks to build the pipeline of
discoveries from inside and outside the company's own walls.

Related information: www.abbvie.com/research-innovation/focus-areas.html

A Focus on Patients
AbbVie is focused on developing specialty pharmaceuticals that address
complex, unsolved health problems, particularly chronic diseases, that now
account for 75 percent of all healthcare costs. By developing new specialty
treatments that improve patient outcomes, AbbVie and its people are helping to
reduce the long-term health and economic impact of these conditions.

Related information: www.abbvie.com/responsibility/patients-first/home.html

Dedicated Employees to Build the Future
AbbVie's 21,000 employees around the world are dedicated to meeting the needs
of patients. They have the freedom, expertise, and ability to innovate and
discover solutions to the world's most pressing health needs.

"Our commitment at AbbVie is to build on Abbott's 125-year heritage and
address some of the world's most serious health issues," Gonzalez said. "We
intend AbbVie's enduring legacy to be one of finding treatments for patients
with serious health care needs."

AbbVie will be listed on the NYSE and NYSE Euronext Paris beginning today
under the ticker symbol "ABBV". A live webcast of the Opening Bell, beginning
today at 9:29 a.m. EST, will be available on the NYSE website. Photos and an
archived video of the bell ringing will be available on Facebook (NYSE
Euronext-Official Site), YouTube (nysetv1), and Twitter (@NYSEEuronext),
#NYSEBell.

AbbVie Facts

  oCorporate Headquarters: North Chicago, Illinois, USA
  oExecutive Leadership Team:

       oRichard A. Gonzalez, Chairman of the Board and Chief Executive
         Officer
       oLaura J. Schumacher, Executive Vice President, Business Development,
         External Affairs and General Counsel
       oWilliam J. Chase, Executive Vice President, Chief Financial Officer
       oCarlos Alban, Executive Vice President, Commercial Operations
       oJohn M. Leonard, M.D., Senior Vice President, Chief Scientific
         Officer
       oTimothy J. Richmond, Senior Vice President, Human Resources

Becoming AbbVie
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott. AbbVie combines the focus and
passion of a leading-edge biotech with the expertise and structure of a
long-established pharmaceutical leader. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to develop and
market advanced therapies that address some of the world's most complex and
serious diseases.

AbbVie aims to help patients live healthier lives and collaborate on
sustainable healthcare solutions. In 2013, AbbVie will employ approximately
21,000 people worldwide and market medicines in more than 170 countries. For
further information on the company and its people, portfolio and commitments,
please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our
Facebookor LinkedIn page.

Forward-Looking Statements
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. AbbVie
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect AbbVie's
operations are discussed in the "Risk Factors" section ofthe Information
Statement attached to our Form 10 Registration Statement, which has been filed
with the SEC, and are incorporated by reference. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking statements as
a result of subsequent events or developments, except as required by law.

Media:
Greg Miley
(847) 938-4898
gregory.miley@abbvie.com

Adelle Infante
(847) 938-8745
adelle.infante@abbvie.com

Investors:
Larry Peepo
(847) 935-6722
larry.peepo@abbvie.com

Liz Shea
(847) 935-2211
liz.shea@abbvie.com

[1] Synagis is a trademark of MedImmune



SOURCE AbbVie

Website: http://www.abbvie.com
 
Press spacebar to pause and continue. Press esc to stop.